Award
NIH Reporter #5R01CA272771-04
The role of USP27X-Cyclin D1 axis in HER2 Therapy Resistant Breast Cancer
Recipient
Roswell Park Cancer Institute, Buffalo, NY
Award Amount
$468,436.00
Ceiling
$468,436.00
Awarded
February 27, 2026
Identifier
5R01CA272771-04
The award supports research on the USP27X enzyme's regulation of Cyclin D1 in HER2 therapy-resistant breast cancer, aiming to develop new therapeutic strategies to overcome drug resistance.
Description
This project aims to understand USP27X's role in CCND1 regulation and its potential as a therapeutic target in overcoming resistance to HER2-targeting agents in breast cancer patients. USP27X is a deubiquitinating enzyme critical for CCND1 stability, and its inhibition could reduce tumor growth and increase sensitivity to HER2 and CDK4/6 inhibitors.